STAT+: Pfizer’s Wall Street critic-turned-executive digs into the company’s problems, obesity plans

Andrew Baum, Pfizer's chief strategy and innovation officer, talked Thursday about the pharmaceutical company's drug development, including its obesity drug danuglipron.